{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-43.0","upperLimit":"20.0","value":"-7.9"},{"groupId":"OG001","lowerLimit":"-20","upperLimit":"20","value":"-2.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"The combined score on the FACT-Ntx TOI is of interest. The FACT-Ntx TOI has 25 items and the score ranges from 0 (worst possible quality of life) -100 (best possible quality of life). The primary QOL endpoint is defined as the change in the FACT-Ntx TOI score from registration to 6 months post consolidation treatment.","dispersionType":"Full Range","groups":[{"description":"Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib, dexamethasone and lenalidomide. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11; fixed dose of lenalidomide at 15 mg orally on days 1-14; and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15. Aspirin 325 mg/day orally on days 1-21 of each cycle was required unless the patient was treated with alternate prophylaxis of either low molecular weight heparin or coumadin.\n\nbortezomib: Given IV\n\nlenalidomide: Given PO\n\ndexamethasone: Given PO","id":"OG000","title":"Arm A (VRD)"},{"description":"Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib plus dexamethasone. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11 and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15.\n\nbortezomib: Given IV\n\ndexamethasone: Given PO","id":"OG001","title":"Arm B (VD)"}],"paramType":"MEAN","populationDescription":"Patients with both assessments complete at baseline and 6 months post consolidation treatment were included in this analysis.","reportingStatus":"POSTED","timeFrame":"Baseline and 6 months post consolidation treatment","title":"Change in Quality of Life (QOL) From Baseline to 6 Months Post Consolidation as Assessed by the Functional Assessment of Cancer Therapy-Neurotoxicity Trial Outcome Index (FACT-Ntx TOI)","type":"SECONDARY","unitOfMeasure":"units on a scale"}